Fluvas is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ... Read more Fluvas is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD Slow the progression of atherosclerosis in patients with CHD.
Fluvastatin acts by competitively inhibiting HMG-CoA reductase, the enzyme for cholesterol synthesis. It reduces total cholesterol, triglycerides, LDL and VLDL concentrations in plasma. It also increases HDL concentrations.
General Dosing Information : Fluvastatin 20 mg to 80 mg/day. This can be administered orally as a single dose, with or without food. Do not break, crush or chew or open capsules prior to administration. Do not take two Fluvastatin 40 mg at one time. Since the maximal effect of a given dose is seen within 4 weeks, periodic lipid determinations should be performed at this time and dosage adjusted according to the patient’s response to therapy and established treatment guidelines. Adult Patients with Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia : The recommended starting dose is one 40 mg Fluvastatin capsule in the evening, or one 40 mg capsule twice daily. Do not take two 40 mg capsules at one time. The recommended starting dose for is one 80 mg administered as a single dose at any time of the day. Pediatric Patients (10-16 years of age) with Heterozygous Familial Hypercholesterolemia : The recommended starting dose is one 20 mg Fluvastatin capsule. Dose adjustments, up to a maximum daily dose administered either as 40 mg twice daily or 80 mg once daily should be made at 6 week intervals. Doses should be individualized according to the goal of therapy.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Most frequent adverse reactions (rate ≥2% and > placebo) are: headache, dyspepsia, myalgia, abdominal pain and nausea.
Hypersensitivity to any component of this medication Active liver disease or unexplained, persistent elevations in serum transaminases Women who are pregnant or may become pregnant Nursing mothers
Cyclosporine : Combination increases Fluvas exposure. Limit dose to 20 mg Fluconazole : Combination increases Fluvas exposure. Limit dose to 20 mg Concomitant lipid-lowering therapies : Use with fibrates or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Glyburide : Monitor blood glucose levels when Fluvas dose is changed Phenytoin : Monitor plasma phenytoin levels when Fluvas treatment is initiated or when the dosage is changed Warfarin and coumarin derivates : Monitor prothrombin times when Fluvas co-administration is initiated, discontinued, or the dosage changed.
Skeletal muscle effects (e.g. myopathy and rhabdomyolysis): Risks increase with advanced age (>65), uncontrolled hypothyroidism, renal impairment, and combination use with cyclosporine, or gemfibrozil. Patients should be advised to report promptly any symptoms of myopathy. This therapy should be discontinued if myopathy is diagnosed or suspected. Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter.